

**Supplementary Table 3.** Patient characteristics of included studies in the systematic literature review and meta-analysis

Reference	Male (%)	Age, years	AST (IU/L)	ALT (IU/L)	Baseline LS (kPa)	Baseline FIB-4	Genotype (%)
Kim et al. <sup>3</sup>	58.0	59.4 (51.7–68.8)	44 (27–75)	38 (22–73)	8.0 (5.6–14.0)	N/A	1 (52.0); 2 (46.0); 3 (1.0); 4 (0.5); 6 (0.5)
Nakai et al. <sup>1</sup>	45.7	66 (16–92)	40 (10–342)	38 (5–389)	7.1 (2.9–66.4)	2.72 (0.29–82.8)	1 (63.3); 2 (34.4); others (2.3)
Pons et al. <sup>2</sup>	49.3	63.7 (11.1)	N/A	103 (67)	20.2 (10.4)	N/A	1 (85.8); 2 (1.8); 3 (6.8); 4 (5.6)
Rimaldi et al. <sup>3</sup>	55.4	68 (61–74)	N/A	N/A	25.5 (18–35.6)	N/A	1 (76.7); 2 (18.6); 3 (3.2); 4 (1.6)
Wang et al. <sup>4</sup>	49.2	54.1±10.8	>40 (10.4%)	>40 (15.2%)	7.7 ± 6.1	N/A	1 (32.3); others (63.8)
Liu et al. <sup>5</sup>	42.0	65±11	N/A	77 (49–137)	13.4 (10.5–22.3)	3.98 (2.67–6.11)	1 (67.0); others (33.0)
Kuo et al. <sup>6</sup>	42.2	63.8±10.3	>40 (12.8%)	>40 (11.0%)	12.0±9.3	2.87±1.99	1 (56.5); 2 (38.9); other (4.6)
Morisco et al. <sup>7</sup>	54.8	64.1±11.7	N/A	N/A	19.2 (7.9)	N/A	1 (80.3); 2 (13.6); 3 (3.8); 4 (2.1); others (0.1)
Zou et al. <sup>8</sup>	24.5	56.7 (8.3)	N/A	N/A	N/A	>3.25 (39.0%)	N/A
Ideno et al. <sup>9</sup>	54.6	65 (24–90)	33.5 (7–367)	34 (9–436)	N/A	3.38 (0.4–5.38)	1 (68.8); 2 (29.9); others (1.3)
Kumada et al. <sup>10</sup>	49.0	62 (53–70)	21 (18–26)	15 (11–20)	N/A	1.86 (1.26–2.69)	1 (57.9); 2 (41.9); 3 (0.2)
Azzi et al. <sup>11</sup>	62.1	60.1 (10.5)	N/A	N/A	N/A	3.65 (3.41)	1 (68.9); 2 (4.6); 3 (12.6); 4 (12.3); others (1.7)
Caviglia et al. <sup>12</sup>	57.6	65 (57–77)	24 (20–29)	20 (16–25)	N/A	N/A	N/A
Tada et al. <sup>13</sup>	40.9	68 (59.4–76)	23 (19–28)	15 (12–21)	N/A	2.41 (1.65–3.45)	1 (72.0); 2 (27.4); others (0.6)
Ampuero et al. <sup>14</sup>	65.4	57.3±9.9	83±54	92±64	19.9±12.3	N/A	N/A
Tahata et al. <sup>15</sup>	41.7	69 (60–76)	39 (28–58)	38 (24–61)	N/A	N/A	1 (77.3); 2 (22.1); others (0.6)
Ide et al. <sup>16</sup>	39.3	64.6±11.9	51.0±35.6	51.8±45.5	N/A	3.86±3.22	1 (78.0); 2 (21.7); 1+2 (0.3)
Hiraoka et al. <sup>17</sup>	44.7	66.9±11.0	24.1±10.3	17.8±11.6	N/A	2.76±1.77	1 (71.1); 2 (28.9)
Kramer et al. <sup>18</sup>	96.4	61.5±7.6	N/A	N/A	N/A	<1.45 (41.9%); 1.45–3.25 (45.9%); >3.25 (11.5%)	1a (55.1); 1a/1b (3.26); 1b (21.45); 1–unknown (2.4); 2 (9.46); 3 (5.66); 4/5/6 (0.95)
Ogawa et al. <sup>19</sup>	42.4	66 (58–73)	36 (26–56)	32 (21–53)	7.5 (5.4–11.4)	N/A	1 (72.4); 2 (26.6)
Tamaki et al. <sup>20</sup>	42.4	67 (58–75)	23 (19–28)	16 (12–22)	N/A	2.31 (1.59–3.32)	N/A

Values as median (interquartile range) or mean±standard deviation.

AST, aspartate aminotransferase; ALT, alanine aminotransferase; LS, liver stiffness; FIB-4, fibrosis-4 index; N/A, not available.

<sup>a</sup>Studies lacking data on the characteristics of the entire patient cohort were excluded.